tiprankstipranks
Advertisement
Advertisement

ELVN Stock Latest News

Enliven price target raised to $62 from $45 at Mizuho
The FlyEnliven price target raised to $62 from $45 at Mizuho
3d ago
ELVN
Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning
PremiumRatings
Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning
24d ago
ELVN
Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress
PremiumThe Fly
Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress
24d ago
ELVN
Guggenheim starts Enliven with Buy on leukemia opportunity
PremiumThe Fly
Guggenheim starts Enliven with Buy on leukemia opportunity
24d ago
ELVN
Enliven initiated with a Buy at Guggenheim
PremiumThe Fly
Enliven initiated with a Buy at Guggenheim
25d ago
ELVN
Enliven price target raised to $59 from $41 at Goldman Sachs
PremiumThe FlyEnliven price target raised to $59 from $41 at Goldman Sachs
28d ago
ELVN
Phil Nadeau Reiterates Buy on Enliven, Citing Strong ELVN-001 Early Data, Clear Pivotal Path, and Solid Cash Runway to 2029
Premium
Ratings
Phil Nadeau Reiterates Buy on Enliven, Citing Strong ELVN-001 Early Data, Clear Pivotal Path, and Solid Cash Runway to 2029
28d ago
ELVN
Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway
Premium
Ratings
Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway
29d ago
ELVN
Enliven reports Q1 EPS (38c) vs. (57c) last year
PremiumThe Fly
Enliven reports Q1 EPS (38c) vs. (57c) last year
29d ago
ELVN
Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho
PremiumThe Fly
Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho
1M ago
MRK
ELVN
Enliven price target raised to $55 from $36 at Clear Street
PremiumThe Fly
Enliven price target raised to $55 from $36 at Clear Street
1M ago
ELVN
Enliven Therapeutics: Strengthening ELVN-001 Profile and M&A Optionality Support Buy Rating and $56 Price Target
PremiumRatings
Enliven Therapeutics: Strengthening ELVN-001 Profile and M&A Optionality Support Buy Rating and $56 Price Target
2M ago
ELVN
Leveraging Merck–Terns Benchmark: Supporting Enliven’s ELVN-001 Upside and a Raised $60 Buy Target
PremiumRatingsLeveraging Merck–Terns Benchmark: Supporting Enliven’s ELVN-001 Upside and a Raised $60 Buy Target
2M ago
ELVN
Enliven rises 11.0%
Premium
The Fly
Enliven rises 11.0%
2M ago
ELVN
Enliven price target raised to $56 from $48 at H.C. Wainwright
Premium
The Fly
Enliven price target raised to $56 from $48 at H.C. Wainwright
2M ago
ELVN
Clear Street says Merck’s bet on TERN-701 sharpens investment case for ELVN-001
PremiumThe Fly
Clear Street says Merck’s bet on TERN-701 sharpens investment case for ELVN-001
2M ago
MRK
NVS
Video: Arm jumps as analysts react favorably to business model shift, guidance
PremiumThe Fly
Video: Arm jumps as analysts react favorably to business model shift, guidance
2M ago
ARM
MRK
Enliven up 20% after Terns Pharmaceuticals agrees to be bought by Merck
PremiumThe Fly
Enliven up 20% after Terns Pharmaceuticals agrees to be bought by Merck
2M ago
MRK
ELVN
Enliven price target raised to $45 from $41 at Mizuho
PremiumThe Fly
Enliven price target raised to $45 from $41 at Mizuho
2M ago
ELVN
Enliven Therapeutics: Compelling Early ELVN-001 Data and De-Risked Development Path Support Buy Rating
PremiumRatingsEnliven Therapeutics: Compelling Early ELVN-001 Data and De-Risked Development Path Support Buy Rating
3M ago
ELVN
Enliven Therapeutics: Compelling ELVN-001 CML Data, Strong Cash Runway Support Buy Rating
Premium
Ratings
Enliven Therapeutics: Compelling ELVN-001 CML Data, Strong Cash Runway Support Buy Rating
3M ago
ELVN
Enliven reports Q4 EPS (48c), consensus (47c)
Premium
The Fly
Enliven reports Q4 EPS (48c), consensus (47c)
3M ago
ELVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >